Bangalore, India -- (SBWIRE) -- 10/17/2017 -- Bone Marrow Transplant Rejection - Pipeline Review, H2 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights
Bone Marrow Transplant Rejection - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 22, 12, 47, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 14 and 2 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 442 pages "Bone Marrow Transplant Rejection - Pipeline Review, H2 2017" report covers Introduction, Bone Marrow Transplant Rejection - Overview, Bone Marrow Transplant Rejection - Therapeutics Development, Bone Marrow Transplant Rejection - Therapeutics Assessment, Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development, Bone Marrow Transplant Rejection - Drug Profiles, Bone Marrow Transplant Rejection - Dormant Projects, Bone Marrow Transplant Rejection - Discontinued Products, Bone Marrow Transplant Rejection - Product Development Milestones, Appendix. This report Covered Companies few are - AbbVie Inc, AbGenomics International Inc, Allergan Plc, Amunix Operating Inc, AnaptysBio Inc, apceth Biopharma GmbH, Aptevo Therapeutics Inc, arGEN-X BV, Athersys Inc, Bellicum Pharmaceuticals Inc, Bio-Cancer Treatment International Ltd, Biogen Inc, Bristol-Myers Squibb Company, Capricor Therapeutics Inc, Cell Source Inc, Cell2B Advanced Therapeutics SA, CellECT Bio Inc, Cleveland BioLabs Inc, Commence Bio Inc, Compugen Ltd, Cynata Therapeutics Ltd, Cytodyn Inc, Escape Therapeutics Inc, F. Hoffmann-La Roche Ltd.

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/bone-marrow-transplant-rejection-pipeline-review-h2-2017

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Cat Allergy - Pipeline Review, H2 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/cat-allergy-pipeline-review-h2-2017

Osteoarthritis - Pipeline Review, H2 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/osteoarthritis-pipeline-review-h2-2017

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.